Assessment of non-vitamin K antagonist oral anticoagulants for the management of left ventricular thrombus

Shunhui Li MS1 | Yuqing Deng MD1 | Yifan Tong MD1 | Qiangzhen Xiong MS2 | Jing Hu MS1 | Xiaojie Jiang MS1 | Tao He MS1 | Liyun Liu MS1 | Hui Chen MS1

1Department of Cardiovascular Medicine, The Third Affiliated Hospital of Nanchang University, Nanchang, China
2Nursing department, The Third Affiliated Hospital of Nanchang University, Nanchang, China

Correspondence
Liyun Liu and Hui Chen. Department of Cardiovascular Medicine, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330008, China.
Email: 1098367330@qq.com (L.L.) and garden80@sina.com (H.C.)

Abstract
Although several studies have assessed the effect of non-vitamin K antagonist oral anticoagulants (NOACs) relative to that of vitamin K antagonists (VKAs) in patients with left ventricular thrombus, the results remain controversial. Herein, a meta-analysis was performed to compare the effectiveness and safety of NOACs versus VKAs for the treatment of left ventricular thrombus. We systematically searched the Cochrane Library, PubMed and Embase databases until November 2020 for studies that compared the effects of NOACs versus VKAs in patients with left ventricular thrombus. The treatment effects were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and pooled by a random-effects model. Seven retrospective studies involving 865 patients with left ventricular thrombus (266 NOAC and 599 VKA users) were included. The pooled analysis suggested no difference in the rate of thrombus resolution between the NOAC and VKA groups (OR = 0.83, 95% CI 0.61–1.13). There were also no differences in the rates of stroke or systemic embolism (OR = 0.62, 95% CI 0.20–1.97), bleeding events (OR = 0.73, 95% CI 0.37–1.45), or all-cause death (OR = 0.92, 95% CI 0.50–1.69) between patients treated with NOACs and those treated with VKAs. In addition, the rates of thrombus resolution, stroke or systemic embolism, bleeding events, and all-cause death between NOAC- and warfarin-treated patients were also similar. Our current evidence suggested that NOAC and VKA users had similar rates of thrombus resolution and clinical outcomes among patients with left ventricular thrombus. Further large-scale prospective studies should confirm our results.

KEYWORDS
anticoagulants, effectiveness, safety, ventricular thrombus, warfarin

1 INTRODUCTION

Left ventricular thrombus is a complication of cardiac diseases such as acute myocardial infarction, heart failure, and nonischemic cardiomyopathy.1-3 With the rapid development of percutaneous coronary intervention, the incidence of left ventricular thrombus caused by acute myocardial infarction has decreased in recent years. In contrast, heart failure with reduced ejection fraction is currently the main cause of left ventricular thrombus. Several studies have demonstrated that left ventricular thrombus is associated with increased risk of stroke or...
systemic embolism and substantial morbidity and mortality.\textsuperscript{4} Therefore, patients with left ventricular thrombus often require anticoagulation therapy. Vitamin K antagonists (VKAs), such as warfarin, are recommended by expert consensus and guidelines and are clinically used for anticoagulation therapy in patients with left ventricular thrombus.\textsuperscript{5} However, VKAs have several shortcomings, including marked inter- and intra-individual variations in medication dosage, a narrow therapeutic window, frequent international normalized ratio monitoring, and many drug–drug or drug–food interactions.\textsuperscript{6} In recent years, non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced for stroke prevention in patients with atrial fibrillation (AF). Novel drugs, including one direct thrombin inhibitor (dabigatran) and three direct Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could improve the disadvantages of VKAs mentioned above. Evidence from randomized clinical trials and observational studies consistently demonstrated that NOACs are at least as effective as VKAs for stroke prevention and sometimes have better improved safety profiles in Asian or non-Asian patients with AF.\textsuperscript{7–11} As such, NOACs have currently been recommended as first-line oral anticoagulants in the AF guidelines.\textsuperscript{12–15}

However, the effectiveness and safety of off-label use of NOACs to treat left ventricular thrombus are still unclear.\textsuperscript{16} Several previous reviews qualitatively described that off-label use of NOACs could be a reasonable and valid option for the treatment of left ventricular thrombus.\textsuperscript{5,17} However, these studies did not compare the effectiveness and safety of NOACs and VKAs in treating left ventricular thrombus. Moreover, there are still no direct head-to-head randomized clinical trials for this purpose. In recent years, several observational studies have assessed the effect of NOACs relative to that of VKAs in patients with left ventricular thrombus, but the results remain contradictory.\textsuperscript{18–24} Therefore, we quantitatively performed a meta-analysis of observational studies comparing the effectiveness and safety of NOACs and VKAs on the rates of thrombus resolution and clinical outcomes in patients with left ventricular thrombus.

\section{METHODS}

As described previously, our current meta-analysis was conducted according to Cochrane methodological standards, and the presentations were performed under the preferred reporting items for reporting systematic reviews and meta-analyses.\textsuperscript{9} Ethical approval was not necessary because no patients were involved in setting the research question, the outcome measures, the design, or the implementation of this meta-analysis. The data, methods, and materials of this meta-analysis are available to others for purposes of reproducing the results or replicating procedures by contacting the corresponding author.

\subsection{Literature search strategy}

Two reviewers systematically searched the Cochrane Library, PubMed and Embase databases until November 2020 for studies that compared the effectiveness and/or safety of any NOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) with that of VKAs in patients with ventricular thrombus. The following key words and their similar search terms were combined using the Boolean operator “and”: (1) ‘ventricular thrombus’ OR ‘intraventricular thrombus’ OR ‘ventricular thrombi’; (2) ‘non-vitamin K antagonists’ OR ‘NOAC’ OR ‘new oral anticoagulants’ OR ‘novel oral anticoagulants’ OR ‘direct oral anticoagulants’ OR ‘DOAC’ OR ‘oral thrombin inhibitors’ OR ‘oral factor Xa inhibitors’ OR ‘dabigatran’ OR ‘rivaroxaban’ OR ‘apixaban’ OR ‘edoxaban’; and (3) ‘vitamin K antagonists’ OR ‘VKA’ OR ‘coumadin’ OR ‘acenocoumarol’ OR ‘phenprocoumon’ OR ‘warfarin’. In addition, we further searched the reference lists of the included studies to identify additional studies. We did not apply any restriction on the language of publication.

\subsection{Inclusion and exclusion criteria}

Studies were eligible if they met the following criteria: (1) design of the study: observational prospective or retrospective study; (2) study population: patients with ventricular thrombus, regardless of the etiology, such as heart failure with reduced ejection fraction, acute myocardial infarction, and nonischemic cardiomyopathy; (3) comparisons: any NOAC (dabigatran, rivaroxaban, edoxaban, or apixaban; any dose) versus VKAs (e.g., coumadin, acenocoumarol, phenprocoumon, and warfarin); (4) clinical outcomes: thrombus resolution, stroke or systemic embolism, bleeding events, and all-cause death. We accepted the original definitions of the included studies; and (5) follow-up duration: no restrictions.

Certain publication types (e.g., reviews, case series, case reports, meta-analyses, editorials, and conference abstracts) or studies with insufficient data were excluded. If the study population had a substantial overlap among different studies, we included the study with the longest follow-up or largest sample size.

\subsection{Data extraction}

All of the retrieved studies were independently screened by two reviewers. The first phase of screening was performed by reading the titles and abstracts of the records. Then, the second phase of screening involved reviewing the full text of the studies to identify potentially eligible studies. Discrepancies were resolved through discussion or dealt with by consultation with a third reviewer. Ultimately, we included the studies that met the eligibility criteria mentioned above. For each included study, the following basic information was collected: study characteristics (e.g., the first author and publication year, study design, study period), patient characteristics (e.g., age, sex), type of NOACs, type of VKAs, follow-up time, and outcomes of interest. In the NOAC or VKA groups, the number of events, event rates, and sample size were extracted for the reported outcomes (thrombus resolution, stroke or systemic embolism, bleeding events, and all-cause death).
2.4 | Quality assessment

The Newcastle–Ottawa Scale (NOS) tool was used to assess the quality of observational studies. This tool had a total score of nine points. Each included study was awarded a maximum of one point for each numbered item within the selection of cohorts (four points), the comparability of cohorts (two points), and the assessment of the outcome (three points). In this meta-analysis, we defined an NOS score of ≥6 points and <6 points as moderate-to-high quality and low quality, respectively.6,25,26

2.5 | Statistical analysis

The Cochrane Q test and \( I^2 \) statistic were used to assess consistency across the included studies. For the Q statistic, a \( p \) value of <.1 indicated substantial heterogeneity. For the \( I^2 \) statistic, 25% or less, 50%, and 75% or more indicated low, moderate, and high heterogeneity, respectively. For each study, the number of events and sample size in each treatment group were pooled by a random-effects model. The pooled treatment effects were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity analysis was performed to examine the influence of each study on the pooled results. We also reperformed the analysis by using a fixed-effects model. Publication bias was visually assessed by using a funnel plot. All statistical analyses were performed by using Review Manager Version 5.3 (the Nordic Cochrane Center, Rigshospitalet, Denmark; http://ims.cochrane.org/revman). The statistical significance threshold was set at a \( p \) value of <.05.

3 | RESULTS

3.1 | Study selection

The literature retrieval process of this meta-analysis is presented in Figure 1. We identified 231 studies through the Cochrane Library, PubMed and Embase electronic databases after we excluded duplicate publications. Based on the title/abstract screenings, 110 studies were excluded according to the predefined criteria. Then, three conference abstracts were excluded based on the full text screenings (Table S1). Finally, a total of seven observational retrospective studies that were published in 202018-24 involving 865 patients with left ventricular thrombus (\( n = 266 \) for NOACs and \( n = 599 \) for VKAs) were included in this meta-analysis.

3.2 | Study characteristics

The baseline characteristics of these included studies are shown in Table 1. Five studies used warfarin as the reference, while the combined VKAs, including warfarin, acenocoumarol, and fluindione, were regarded as the control group in the study by Daher et al.20

3.3 | Effect of NOACs versus that of VKAs on thrombus resolution

All seven included studies reported the rate of thrombus resolution. A total of 154 events were found in 266 patients with NOACs, and 386 events were observed in 599 patients with VKAs. As shown in Figure 2, a random-effects model analysis suggested no difference in the rate of thrombus resolution between the NOAC and VKA groups.
No heterogeneity was found across the included studies (Q statistic: \( p = .79 \), and \( I^2 = 0\% \)).

### 3.5 Effect of NOACs versus that of VKAs on bleeding events

A total of five included studies assessed the effect of NOACs versus that of VKAs on bleeding risks. In the study by Guddeti et al., bleeding events, defined as any life-threatening bleeding, drop in hemoglobin \( \geq 2 \) g, and/or bleeding requiring hospitalization or evaluation by endoscopy, were observed in five patients. Iqbal et al. used clinically relevant bleeding and defined three episodes of gastrointestinal bleeding (one requiring hospitalization or blood transfusion) and three epistaxis events (0 requiring hospitalization or blood transfusion). Jones et al. defined bleeding events using the BARC criteria, and they only presented the specific data of major bleeding events (BARC >2). Robinson et al. reported bleeding events requiring cessation in anticoagulation. Cochran et al. included minimal, minor, and major bleeding assessed by Thrombolysis in Myocardial Infarction bleeding criteria. As shown in Figure 3, the pooled data suggested no difference in the rate of bleeding events between NOACs and VKAs (OR = 0.73, 95% CI 0.37–1.45; \( p = .37 \)). We found no heterogeneity (Q statistic: \( p = .67 \), and \( I^2 = 0\% \)).

### 3.6 Effect of NOACs versus that of VKAs on all-cause death

Two studies assessed the effect of NOACs versus that of VKAs on all-cause death. A random-effects model analysis suggested that the event rate of all-cause death between NOACs and VKAs was not significantly different (OR = 0.92, 95% CI 0.50–1.69; \( p = .79 \)), with no heterogeneity of this part (Q statistic: \( p = .49 \), and \( I^2 = 0\% \)). The results of this part should be interpreted cautiously due to the limited number of included studies.

### 3.7 Sensitivity analysis

After exclusion of one study at a time, the corresponding results were not changed substantially. We only included the six included studies that used warfarin as the reference and reperformed the
aforementioned analyses. Pooling data from these studies showed no differences between NOACs and warfarin in the event rates of thrombus resolution, stroke or systemic embolism, bleeding events, or all-cause death (all \( p > 0.05 \); Figures S1 and S2). In addition, we also reperformed the analysis with a fixed-effects model, which suggested that NOACs versus VKAs yielded nonsignificantly different risks for the outcomes of thrombus resolution, stroke or systemic embolism, bleeding events, and all-cause death (Figures S3 and S4).

**FIGURE 2** The outcome of thrombus resolution between NOACs versus VKAs. Abbreviations: OR, odds ratio; CI, confidence interval; NOACs, non-vitamin K antagonist oral anticoagulants; VKAs, vitamin K antagonists

| Study or Subgroup | NOACs | VKAs | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|-------|------|--------------------------------|--------------------------------|
| Ali et al (2020)  | 18    | 32   | 12.4% | 0.80 [0.33, 1.91]          |
| Cochran et al (2020) | 12    | 14   | 59.3% | 1.87 [0.97, 3.58]          |
| Daher et al (2020) | 12    | 17   | 42.1% | 0.96 [0.28, 3.32]          |
| Guddelli et al (2020) | 15   | 19   | 80.2% | 0.94 [0.27, 3.21]          |
| Iqbal et al (2020) | 13    | 22   | 62.9% | 0.69 [0.25, 1.88]          |
| Jones et al (2020) | 20    | 41   | 60.1% | 1.34 [0.59, 3.10]          |
| Robinson et al (2020) | 56  | 121  | 236.9% | 0.69 [0.44, 1.07]          |
| Total (95% CI)    | 266   | 599  | 100.0% | 0.83 [0.61, 1.13]          |
| Total events      | 154   | 386  |                  |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 3.12, df = 6 (\( p = 0.79 \)); I² = 0% | Test for overall effect: \( Z = 1.20 (p = 0.23) \) |

**FIGURE 3** The outcomes of stroke or systemic embolism, bleeding events, and all-cause death between NOACs versus VKAs. Abbreviations: OR, odds ratio; CI, confidence interval; NOACs, non-vitamin K antagonist oral anticoagulants; VKAs, vitamin K antagonists

### 1.1 Stroke or Systemic Embolism

| Study or Subgroup | NOACs | VKAs | Odds Ratio M-H, Random, 95% CI |
|-------------------|-------|------|--------------------------------|
| Ali et al (2020)  | 2     | 32   | 16.8% | 0.18 [0.04, 0.88]          |
| Cochran et al (2020) | 0    | 14   | 59.4% | 0.18 [0.01, 3.34]          |
| Daher et al (2020) | 2     | 17   | 42.5% | 1.27 [0.23, 6.88]          |
| Guddelli et al (2020) | 0   | 19   | 80.2% | 0.81 [0.04, 17.46]         |
| Iqbal et al (2020) | 0     | 22   | 62.5% | 0.54 [0.02, 11.64]         |
| Jones et al (2020) | 0     | 41   | 60.1% | 0.15 [0.01, 2.89]          |
| Robinson et al (2020) | 17   | 121  | 236.9% | 2.95 [0.23, 5.48]         |
| Subtotal (95% CI)  | 266   | 599  | 100.0% | 0.62 [0.20, 1.97]          |
| Total events      | 21    | 51   |                  |                               |
| Heterogeneity: Tau² = 1.23; Chi² = 14.39, df = 6 (\( p = 0.03 \)); I² = 58% | Test for overall effect: \( Z = 0.81 (p = 0.42) \) |

### 1.2 Bleeding Events

| Study or Subgroup | NOACs | VKAs | Odds Ratio M-H, Random, 95% CI |
|-------------------|-------|------|--------------------------------|
| Cochran et al (2020) | 2    | 14   | 59.4% | 1.06 [0.20, 5.66]          |
| Guddelli et al (2020) | 1   | 19   | 80.2% | 1.06 [0.11, 10.02]         |
| Iqbal et al (2020) | 0    | 22   | 62.5% | 0.19 [0.01, 3.57]          |
| Jones et al (2020) | 0    | 41   | 60.1% | 0.15 [0.01, 2.89]          |
| Robinson et al (2020) | 8    | 121  | 236.9% | 0.81 [0.34, 1.90]         |
| Subtotal (95% CI)  | 217   | 497  | 100.0% | 0.73 [0.37, 1.45]          |
| Total events      | 11    | 41   |                  |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 2.34, df = 4 (\( p = 0.67 \)); I² = 0% | Test for overall effect: \( Z = 0.89 (p = 0.37) \) |

### 1.3 All-Cause Death

| Study or Subgroup | NOACs | VKAs | Odds Ratio M-H, Random, 95% CI |
|-------------------|-------|------|--------------------------------|
| Iqbal et al (2020) | 3    | 22   | 62.5% | 1.47 [0.34, 6.48]          |
| Robinson et al (2020) | 14  | 121  | 236.9% | 0.83 [0.43, 1.63]         |
| Subtotal (95% CI)  | 143   | 298  | 100.0% | 0.92 [0.50, 1.69]          |
| Total events      | 17    | 36   |                  |                               |
| Heterogeneity: Tau² = 0.00; Chi² = 0.47, df = 1 (\( p = 0.49 \)); I² = 0% | Test for overall effect: \( Z = 0.27 (p = 0.79) \) |
3.8 | Publication bias

The publication bias assessed by using funnel plots is shown in Figures S5 and S6. Of note, according to the Cochrane handbook, it is theoretically unsuitable to assess publication bias for the reported effect estimates when the number of included studies is less than 10. Therefore, the results of the publication bias shown by the funnel plots should be interpreted cautiously.

4 | DISCUSSION

In the present study, the pooling results from the seven included studies showed that in patients with left ventricular thrombus, there were similar rates of effectiveness and safety outcomes, including stroke or systemic embolism, bleeding events, and all-cause death, between treatment with NOACs and VKAs. In addition, we did not observe significant differences in thrombus resolution between use of NOACs versus VKAs for oral anticoagulation. Specifically, there were no differences in the event rates of thrombus resolution, stroke or systemic embolism, bleeding events, or all-cause death between NOAC and warfarin treatments. Subsequent randomized controlled trials are warranted to further demonstrate the effectiveness and safety of NOACs and VKAs for this indication.

Left ventricular thrombus is a major complication of several cardiac diseases, such as heart failure, acute myocardial infarction, and cardiomyopathy, resulting in high risk of major adverse cardiovascular events and mortality. The potential mechanisms of thrombus genesis may be due to reduced cardiac output, increased left ventricular volumes, insufficient contractility, and regional wall motion abnormalities. For myocardial infarction-related ventricular thrombus, endocardial surface abnormalities after myocardial infarction (e.g., fibrosis and inflammatory or infiltrative alterations) could result in blood stasis. Moreover, for heart failure-related ventricular thrombus, the hypercoagulable state could accelerate the formation of thrombi. Anticoagulation therapy is required to prevent the risk of stroke and its subsequent mortality in the population of patients with left ventricular thrombi. Indeed, antithrombotic therapy has been found to reduce the risk of mortality in patients with left ventricular thrombus.

Previously, VKAs have often been used to treat left ventricular thrombi. NOACs have been widely used in patients with venous thromboembolism and AF. However, data comparing the off-label use of NOACs for the treatment of left ventricular thrombus are still limited. In our current study, we performed a systematic review and meta-analysis of seven observational studies comparing the effectiveness and safety of NOACs and VKAs on thrombus resolution and clinical outcomes in patients with left ventricular thrombus. We included 993 patients, of whom nearly 70% received VKAs (predominantly warfarin) and 30% received a NOAC. Our results after pooling the existing data suggested that NOACs had effectiveness (as assessed by thrombus resolution, stroke or systemic embolism, bleeding events, and all-cause death) and safety (as assessed by bleeding events) similar to those of VKAs in treating left ventricular thrombus. Our findings were consistent with a prior meta-analysis by Cochran et al. However, in the study by Cochran et al., three of their included studies were published conference abstracts, limiting the validity of the corresponding findings. Based on recent evidence, NOACs at least potentially provide a more convenient alternative for the management of left ventricular thrombus than warfarin because of their ease of administration, absence of monitoring of anticoagulant activity, and fewer drug–drug or drug–food interactions.

In our meta-analysis, NOACs had safety similar to that of VKAs in patients with left ventricular thrombus. However, our results should be interpreted with caution in the context of available evidence, and the small sample size cannot be ignored. A randomized controlled trial is warranted to further assess the safety of NOACs in patients with left ventricular thrombus. Four ongoing randomized clinical trials (NCT 02982590, NCT03232398, NCT03926780, and NCT03764241) may provide more comprehensive insights for this purpose.

Considering the observational nature of the included studies, our data from this meta-analysis were still limited. Until the results from randomized control trials designed to examine the effect of NOACs versus VKAs are available with respect to patients with left ventricular thrombus, our evidence could not provide reliable guidance on the choice of NOACs versus VKAs in real-life patients. Further prospective trials are needed to clarify whether there are more benefits from NOACs than from VKAs for this population. Moreover, the findings in the present meta-analysis were driven by combining different types or doses of NOACs. Due to the limited data, we did not perform a subgroup analysis based on the type or dose of NOAC. Because of the widespread use of NOACs in clinical practice, further study should take the type or dose of NOAC into consideration.

5 | LIMITATIONS

Several limitations should be acknowledged in this meta-analysis. First, with respect to the observational retrospective nature of this meta-analysis, residual confounders might exist. Further study could include propensity score-matched or multivariate adjusted effect estimates to confirm our findings. Second, the rates of some outcomes in the pooled analysis had quite wide CIs, which might be largely due to the limited sample size (five of seven included studies involved fewer than 100 patients) and small number of events. Further large-scale studies with a better design are needed to confirm our results. Third, since small numbers of patients treated with NOACs were included, it was impossible to evaluate the effectiveness and safety of individual NOACs versus VKAs in patients with left ventricular thrombus. Fourth, among VKA users, the time in the therapeutic range (TTR) was not considered because only one included study by Jones et al. compared NOACs versus VKAs with a TTR ≥65%. Finally, the underlying etiology of left ventricular thrombus discovery was different across the included studies.

6 | CONCLUSIONS

Based on previously published studies, our current evidence suggests that NOACs and VKAs have similar rates of thrombus resolution and...
clinical outcomes among patients with left ventricular thrombus. Further large-scale studies with a better design should confirm our results. Clinicians should continue to examine the off-label use of NOACs in the treatment of left ventricular thrombus.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS
Shunhui Li and Xiaojie Jiang: Data curation; Shunhui Li and Jing Hu: Formal analysis; Shunhui Li and Qiangzhen Xiong: Investigation; Shunhui Li and Yuqing Deng: Methodology; Shunhui Li and Yuqing Deng: Software; Liyun Liu and Hui Chen: Supervision; Shunhui Li, Tao He, and Xiaojie Jiang: Validation; Shunhui Li: Writing – original draft; Liyun Liu and Hui Chen: Writing – review & editing.

ORCID
Liyun Liu https://orcid.org/0000-0001-7549-2810

REFERENCES
1. Hooks M, Okasha O, Velangi PS, Nijjar PS, Farzaneh-Far A, Shenoy C. Left ventricular thrombus on cardiovascular magnetic resonance imaging in non-ischaemic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2020. https://doi.org/10.1093/ehjci/jea244.
2. McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JJ, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment. JAMA Cardiol. 2018;3(7):642-649.
3. McCarthy CP, Murphy S, Venkataseswaran RV, et al. Left ventricular thrombus: contemporary etiologies, treatment strategies, and outcomes. J Am Coll Cardiol. 2019;73(15):2007-2009.
4. Lattuca B, Bouziri N, Kerneis M, et al. Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol. 2020;75(14):1676-1685.
5. Sedhom R, Abdelmaseeh P, Megaly M, Asinger R. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: a systematic review. Am J Med. 2020;133(11):1266-1273.
6. Deng Y, Tong Y, Deng Y, Zou L, Li S, Chen H. Non-vitamin K antagonist Oral anticoagulants versus warfarin in patients with cancer and cancer-related thrombosis: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540.
7. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
8. Granger CB, Alexander JH, McMurray JVI, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
11. Xue Z, Zhou Y, Wu C, Lin J, Liu X, Zhu W. Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data. Heart Fail Rev. 2020;25(6):957-964.
12. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5). https://doi.org/10.1093/eurheartj/ehaa612.
13. January CT, Warn LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):R665.
14. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393.
15. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
16. Brokmeier H, Kütt K. Off-label use for direct Oral anticoagulants: valvular atrial fibrillation, heart failure, left ventricular thrombus, superficial vein thrombosis, pulmonary hypertension-a systematic review. Ann Pharmacother. 2020;27546746. https://doi.org/10.1177/1060028020970618.
17. Fledermann AM, Hayes CH, Magalski A, Main ML. Efficacy of direct acting Oral anticoagulants in treatment of left ventricular thrombus. Am J Cardiol. 2019;124(3):367-372.
18. Robinson AA, Tranke CR, Eubanks G, et al. Off-label use of direct Oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020;5(6):685-692.
19. Isqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Failure. 2020;7(5):2032-2041.
20. Daher J, Da Costa A, Hilaire C, et al. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: retrospective comparative study with vitamin K antagonists. Clin Drug Investig. 2020;40(4):343-353.
21. Guddeti RR, Anwar M, Walters RW, et al. Treatment of left ventricular thrombus with direct Oral anticoagulants: a retrospective observational study. Am J Med. 2020;133:1488-1491.
22. Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2020. https://doi.org/10.1089/ehjcp/pvaa096.
23. Ali Z, Isom N, Dalia T, et al. Direct oral anticoagulant use in left ventricular thrombus. Thromb J. 2020;18(1):29.
24. Cochran JM, Jia X, Kaczmarek J, et al. Direct Oral anticoagulants in the treatment of left ventricular thrombi: a retrospective, multicenter study and meta-analysis of existing data. J Cardiovasc Pharmacol Ther. 2020;26(2):187991088. https://doi.org/10.1177/1074289420967644.
25. Zhou Y, Ma J, Zhu W. Efficacy and safety of direct Oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2020;20(1):51-60.
26. Liao X, Fu Y, Ma J, Zhu W, Yuan P. Non-vitamin K antagonist Oral anticoagulants versus warfarin in patients with atrial fibrillation and peripheral artery disease: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2020;34(3):391-399.
27. Chen A, Stecker E, WB A. Direct Oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9:e017559.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Li S, Deng Y, Tong Y, et al. Assessment of non-vitamin K antagonist oral anticoagulants for the management of left ventricular thrombus. Clin Cardiol. 2021;44:754–760. https://doi.org/10.1002/clc.23553